Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Hepatocellular
  • Glypicans
  • Liver Neoplasms

abstract

  • Codrituzumab plus sorafenib were tolerated at 1600 mg q2w and 400 mg bid, respectively, with no responses. Codrituzumab exerts selective distribution to HCC cells, and GPC3 does not show any down-regulation post-progression (NCT00976170).

authors

publication date

  • January 24, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5548107

Digital Object Identifier (DOI)

  • 10.1007/s00280-017-3241-9

PubMed ID

  • 28120036

Additional Document Info

start page

  • 421

end page

  • 429